Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) EBIT: 2016-2024

Historic EBIT for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to -$176.1 million.

  • Cidara Therapeutics' EBIT fell 409.53% to -$88.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$195.5 million, marking a year-over-year decrease of 49.64%. This contributed to the annual value of -$176.1 million for FY2024, which is 550.78% down from last year.
  • As of FY2024, Cidara Therapeutics' EBIT stood at -$176.1 million, which was down 550.78% from -$27.1 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' EBIT registered a high of -$27.1 million during FY2023, and its lowest value of -$176.1 million during FY2024.
  • Its 3-year average for EBIT is -$78.9 million, with a median of -$33.5 million in 2022.
  • In the last 5 years, Cidara Therapeutics' EBIT skyrocketed by 41.19% in 2021 and then slumped by 550.78% in 2024.
  • Cidara Therapeutics' EBIT (Yearly) stood at -$71.8 million in 2020, then spiked by 41.19% to -$42.3 million in 2021, then grew by 20.71% to -$33.5 million in 2022, then grew by 19.23% to -$27.1 million in 2023, then plummeted by 550.78% to -$176.1 million in 2024.